Indian Pharmaceutical Exports Flourish Despite US Pharma Market Slowdown
Pharmaceutical Exports Overview
Indian pharmaceutical exports have remarkably crossed $31 billion in FY26, despite experiencing a sharp slowdown in the US market. The official data indicates a 23% year-on-year decline in March, reflecting the underlying challenges faced by the industry.
Export Challenges and Highlights
- Exports to the US declined by 10% in March, primarily due to overstocking before higher tariffs were introduced.
- Shipments to China contracted 11.54%, reflecting shifts towards high-value imports.
- Despite these setbacks, pharma exports in March FY26 saw a 10.6% growth over February, indicating potential recovery.
Category Performance
Drug formulations and biologicals led overall exports, maintaining a share of 74.2% with a modest growth of 0.7%.
Vaccines stood out as a significant growth area at $1.5 billion, showcasing a robust rise of 26.4% and driving optimism within the sector.
Regional Insights
- NAFTA region exports fell 7.9% to nearly $10.6 billion.
- Exports to the UK and Belgium saw slight declines, while regions like Africa and Oceania experienced notable growth.
The future trajectory indicates a need for adaptation among exporters as market dynamics shift significantly in response to global trends.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.